Performance Evaluation of Abbott RealTime HBV Quantification Kit for HBV Viral Load by Real-Time PCR.
10.3343/kjlm.2008.28.2.144
- Author:
Myeong Hee KIM
1
;
Choong Hwan CHA
;
Dongheui AN
;
Sung Eun CHOI
;
Heung Bum OH
Author Information
1. Department of Laboratory Medicine, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea. hboh@amc.seoul.kr
- Publication Type:Original Article ; English Abstract ; Evaluation Studies
- Keywords:
Real-time PCR;
Hepatitis B virus;
Performance;
Evaluation
- MeSH:
Computer Systems;
DNA, Viral/*blood;
Hepatitis B virus/genetics/*isolation & purification;
Hepatitis B, Chronic/*virology;
Humans;
Polymerase Chain Reaction/*methods;
Reagent Kits, Diagnostic;
Viral Load/*methods
- From:The Korean Journal of Laboratory Medicine
2008;28(2):144-150
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Hepatitis B virus (HBV) DNA quantification is necessary for starting and monitoring of antiviral therapy in patients with chronic hepatitis B. This study was intended to assess the clinical performance of Abbott RealTime HBV Quantification kit (Abbott Laboratories, USA). METHODS: The performance was evaluated in terms of precision, linearity, detection sensitivity, cross-reactivity, and carry-over. A correlation with the Real-Q HBV Quantification kit (BioSewoom Inc., Korea) was also examined using serum samples from 64 patients diagnosed with chronic hepatitis B and underwent lamivudine therapy in Asan Medical Center. We verified the trueness of the system by comparing the outputs with the assigned values of the BBI panel (BBI Diagnostics, USA). RESULTS: Within-run and between-run coefficients of variation (CV) were 3.56-4.71% and 3.03-4.98%, respectively. Linearity was manifested ranging from 53 to 10(9) copies/mL and the detection sensitivity was verified to be 51 copies/mL. None of hepatitis C virus showed cross-reactivity. No cross-contamination occurred when negative and positive samples were alternatively placed in a row. It showed a good correlation with the Real-Q HBV (r2=0.9609) and the test results for the BBI panel were also well agreed to the assigned values (r2=0.9933). CONCLUSIONS: The performance of Abbott RealTime HBV Quantification kit was excellent; thus, it should be widely used in starting and monitoring of antiviral therapy in Korean patients with chronic hepatitis B.
